Homepage084990 • KOSDAQ
add
Helixmith Co Ltd
Vorige slotkoers
₩ 2.960,00
Dag-range
₩ 2.900,00 - ₩ 2.995,00
Jaar-range
₩ 2.115,00 - ₩ 4.950,00
Beurswaarde
133,67 mld. KRW
Gem. volume
174,93K
Koers/winst
-
Dividendrendement
-
Primaire beurs
KOSDAQ
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (KRW) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 930,47 mln. | 13,80% |
Bedrijfskosten | 3,14 mld. | -48,69% |
Netto inkomsten | -1,53 mld. | 71,47% |
Netto winstmarge | -164,30 | 74,93% |
Winst per aandeel | — | — |
EBITDA | -2,32 mld. | 50,15% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
| (KRW) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 81,43 mld. | -8,21% |
Totale activa | 147,20 mld. | -27,05% |
Totale passiva | 6,70 mld. | -87,42% |
Totaal aandelenvermogen | 140,50 mld. | — |
Uitstaande aandelen | 46,05 mln. | — |
Koers-boekwaardeverhouding | 0,97 | — |
Rendement op activa | -4,83% | — |
Rendement op kapitaal | -5,05% | — |
Kasstroom
Nettomutatie in liquide middelen
| (KRW) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -1,53 mld. | 71,47% |
Operationele kasstroom | -1,78 mld. | 69,42% |
Kasstroom uit beleggingen | 35,62 mld. | 1.267,16% |
Kasstroom uit financiering | -118,78 mln. | 99,41% |
Nettomutatie in liquide middelen | 34,01 mld. | 217,30% |
Vrije kasstroom | -1,26 mld. | 62,47% |
Over
Helixmith Co. LTD. is a biotechnology company located in Seoul, South Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis, currently in phase III diabetic peripheral neuropathy in the US. Engensis is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor, HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers, amyotrophic lateral sclerosis, coronary artery disease, claudication, and Charcot-Marie-Tooth disease. Wikipedia
Opgericht
nov 1996
Website
Werknemers
33
